Compare SYPR & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYPR | LPCN |
|---|---|---|
| Founded | 1997 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.0M | 61.8M |
| IPO Year | 1996 | 2011 |
| Metric | SYPR | LPCN |
|---|---|---|
| Price | $2.97 | $2.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 60.8K | ★ 359.2K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $82,294,000.00 | $1,976,677.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $74.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.51 | $1.81 |
| 52 Week High | $4.74 | $12.37 |
| Indicator | SYPR | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 44.41 | 25.37 |
| Support Level | $2.91 | N/A |
| Resistance Level | $3.58 | $3.42 |
| Average True Range (ATR) | 0.25 | 0.59 |
| MACD | -0.04 | -0.23 |
| Stochastic Oscillator | 36.96 | 2.80 |
Sypris Solutions Inc is a USA-based company engaged in providing truck components, oil and gas pipeline components, and aerospace and defense electronics. The company offers a range of manufacturing, engineering, design, and other technical services. The business activity of the firm is functioned through Sypris Technologies and Sypris Electronics segments. Sypris Technologies segment is engaged in the sales of machined, welded, and heat-treated steel components for heavy commercial vehicle and high-pressure energy pipeline applications whereas the Sypris Electronics segment is engaged in the sale of manufacturing services, technical services, and products to customers in the market for aerospace and defense electronics. Sypris derives the revenue from the Technologies segment.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.